Literature DB >> 18158560

Pathology of peripheral neuroblastic tumors: significance of prominent nucleoli in undifferentiated/poorly differentiated neuroblastoma.

Tamás Tornóczky1, Dávid Semjén, Hiroyuki Shimada, Inge M Ambros.   

Abstract

The presence of large cells having simultaneously increased cytoplasmic and nuclear volume accompanied by prominent nucleoli; i.e., differentiating neuroblasts and ganglion cells, is well documented in peripheral neuroblastic tumors (pNTs), and considered as one of the signs of tumor maturation and an indication of a better prognosis of the patients. On the other hand, in 2004 it was reported that large-cell neuroblastoma composed of neuroblastic cells with only nuclear enlargement without recognizable cytoplasmic maturation behaved poorly clinically. Here we are proposing a new pNT subtype in the neuroblastoma category, in addition to the undifferentiated, poorly differentiated and differentiating subtypes: that is large nucleolar neuroblastoma (LNN) characterized by large prominent nucleoli and no or very little amount of discernible cytoplasm. LNN, whose neuroblastic cells are often large in size due to nuclear enlargement, includes those tumors previously categorized into the large-cell neuroblastoma group. LNN tumors, regardless of the size of nuclei, seem to behave aggressively with a very poor prognosis of the patients. It is speculated that nucleolar enlargement without cytoplasmic maturation in LNN tumor cells can be a sign of MYCN amplification.

Entities:  

Mesh:

Year:  2007        PMID: 18158560     DOI: 10.1007/bf02940304

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  14 in total

1.  Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.

Authors:  S Goto; S Umehara; R B Gerbing; D O Stram; G M Brodeur; R C Seeger; J N Lukens; K K Matthay; H Shimada
Journal:  Cancer       Date:  2001-11-15       Impact factor: 6.860

2.  International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.

Authors:  H Shimada; S Umehara; Y Monobe; Y Hachitanda; A Nakagawa; S Goto; R B Gerbing; D O Stram; J N Lukens; K K Matthay
Journal:  Cancer       Date:  2001-11-01       Impact factor: 6.860

3.  The International Neuroblastoma Pathology Classification (the Shimada system).

Authors:  H Shimada; I M Ambros; L P Dehner; J Hata; V V Joshi; B Roald; D O Stram; R B Gerbing; J N Lukens; K K Matthay; R P Castleberry
Journal:  Cancer       Date:  1999-07-15       Impact factor: 6.860

4.  Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee.

Authors:  H Shimada; I M Ambros; L P Dehner; J Hata; V V Joshi; B Roald
Journal:  Cancer       Date:  1999-07-15       Impact factor: 6.860

5.  Morphologic features of neuroblastoma (Schwannian stroma-poor tumors) in clinically favorable and unfavorable groups.

Authors:  Inge M Ambros; Jun-ichi Hata; Vijay V Joshi; Borghild Roald; Louis P Dehner; Heinz Tüchler; Ulrike Pötschger; Hiroyuki Shimada
Journal:  Cancer       Date:  2002-03-01       Impact factor: 6.860

6.  Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients.

Authors:  Jayne M Lamont; Charles S McManamy; Andrew D Pearson; Steven C Clifford; David W Ellison
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

7.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

8.  Large cell neuroblastoma: a distinct phenotype of neuroblastoma with aggressive clinical behavior.

Authors:  Tamás Tornóczky; Endre Kálmán; Pál G Kajtár; Tibor Nyári; Andrew D J Pearson; Deborah A Tweddle; Julian Board; Hiroyuki Shimada
Journal:  Cancer       Date:  2004-01-15       Impact factor: 6.860

9.  Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular.

Authors:  Michel Peuchmaur; Emanuele S G d'Amore; Vijay V Joshi; Jun-ichi Hata; Borghild Roald; Louis P Dehner; Robert B Gerbing; Daniel O Stram; John N Lukens; Katherine K Matthay; Hiroyuki Shimada
Journal:  Cancer       Date:  2003-11-15       Impact factor: 6.860

10.  Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.

Authors:  Chie Kobayashi; Hector L Monforte-Munoz; Robert B Gerbing; Daniel O Stram; Katherine K Matthay; John N Lukens; Robert C Seeger; Hiroyuki Shimada
Journal:  Cancer       Date:  2005-01-01       Impact factor: 6.860

View more
  11 in total

1.  Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.

Authors:  Shizhen Zhu; Jeong-Soo Lee; Feng Guo; Jimann Shin; Antonio R Perez-Atayde; Jeffery L Kutok; Scott J Rodig; Donna S Neuberg; Daniel Helman; Hui Feng; Rodney A Stewart; Wenchao Wang; Rani E George; John P Kanki; A Thomas Look
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

2.  Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.

Authors:  Larry L Wang; Rie Suganuma; Naohiko Ikegaki; Xao Tang; Arlene Naranjo; Patrick McGrady; Wendy B London; Michael D Hogarty; Julie M Gastier-Foster; A Thomas Look; Julie R Park; John M Maris; Susan L Cohn; Robert C Seeger; Hiroyuki Shimada
Journal:  Cancer       Date:  2013-07-30       Impact factor: 6.860

3.  Replicating and identifying large cell neuroblastoma using high-dose intra-tumoral chemotherapy and automated digital analysis.

Authors:  Jordan S Taylor; Lingdao Sha; Naohiko Ikegaki; Jasmine Zeki; Ryan Deaton; Jamie Harris; Jeannine Coburn; Burcin Yavuz; Amit Sethi; Hiroyuki Shimada; David L Kaplan; Peter Gann; Bill Chiu
Journal:  J Pediatr Surg       Date:  2019-08-31       Impact factor: 2.545

4.  Transient treatment with epigenetic modifiers yields stable neuroblastoma stem cells resembling aggressive large-cell neuroblastomas.

Authors:  Naohiko Ikegaki; Hiroyuki Shimada; Autumn M Fox; Paul L Regan; Joshua R Jacobs; Sakeenah L Hicks; Eric F Rappaport; Xao X Tang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-11       Impact factor: 11.205

5.  Preclinical models for neuroblastoma: establishing a baseline for treatment.

Authors:  Tal Teitz; Jennifer J Stanke; Sara Federico; Cori L Bradley; Rachel Brennan; Jiakun Zhang; Melissa D Johnson; Jan Sedlacik; Madoka Inoue; Ziwei M Zhang; Sharon Frase; Jerold E Rehg; Claudia M Hillenbrand; David Finkelstein; Christopher Calabrese; Michael A Dyer; Jill M Lahti
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

6.  Inhibition of hypoxia inducible factors combined with all-trans retinoic acid treatment enhances glial transdifferentiation of neuroblastoma cells.

Authors:  Flora Cimmino; Lucia Pezone; Marianna Avitabile; Giovanni Acierno; Immacolata Andolfo; Mario Capasso; Achille Iolascon
Journal:  Sci Rep       Date:  2015-06-09       Impact factor: 4.379

7.  The pre-rRNA processing factor DEF is rate limiting for the pathogenesis of MYCN-driven neuroblastoma.

Authors:  T Tao; S B Sondalle; H Shi; S Zhu; A R Perez-Atayde; J Peng; S J Baserga; A T Look
Journal:  Oncogene       Date:  2017-03-06       Impact factor: 9.867

8.  MYCN induces neuroblastoma in primary neural crest cells.

Authors:  R R Olsen; J H Otero; J García-López; K Wallace; D Finkelstein; J E Rehg; Z Yin; Y-D Wang; K W Freeman
Journal:  Oncogene       Date:  2017-05-01       Impact factor: 9.867

9.  Presence of differentiating neuroblasts in bone marrow is a favorable prognostic factor for bone marrow metastatic neuroblastoma at diagnosis.

Authors:  Sang Hyuk Park; Sollip Kim; Chan-Jeoung Park; Seongsoo Jang; Hyun-Sook Chi; Kyung-Nam Koh; Ho Joon Im; Jong Jin Seo
Journal:  Ann Lab Med       Date:  2013-02-21       Impact factor: 3.464

10.  ARID1A loss in neuroblastoma promotes the adrenergic-to-mesenchymal transition by regulating enhancer-mediated gene expression.

Authors:  Hui Shi; Ting Tao; Brian J Abraham; Adam D Durbin; Mark W Zimmerman; Cigall Kadoch; A Thomas Look
Journal:  Sci Adv       Date:  2020-07-15       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.